OnabotulinumtoxinA injections compared with saline for trigeminal neuralgia
Compares onabotulinumtoxinA with placebo saline injections in adults with trigeminal neuralgia.
Key facts
- Who runs it
- Stanford University
- Where
- Stanford, United StatesSee the site
- Trial code
- Registry title
- OnabotulinumtoxinA for Trigeminal Neuralgia
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 20 people, planned
- Started
- 1 Jun 2024
- Expected to end
- 1 Sept 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- OnabotulinumtoxinA 100 UNT [Botox]
- Sodium Chloride 0.9% for Injection, Preservative Free
- Record updated
- 22 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with classical trigeminal neuralgia, a severe facial nerve pain. It compares OnabotulinumtoxinA (Botox) skin injections with saline (salt water, placebo) injections.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Classical trigeminal neuralgia by ICHD criteria 13.1.1.1, with more than 10 pain attacks per week. Surgery failed, is not possible, or is not wanted.
- Earlier treatment
- At least 2 medicines tried without enough relief. Medicine doses must have been stable for the last 2 weeks.
Main reasons for not taking part
- Secondary or idiopathic trigeminal neuralgia, or painful trigeminal neuropathy (ICHD 13.1.1.2, 13.1.1.3, 13.1.2)
- Pregnant or breastfeeding
- Neuromuscular disease (a disease of nerves and muscles)
- Taking aminoglycoside antibiotics
- Taking part in other studies
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Men and women age 18 or older
- Judged to be of legal competence
- Sufficient knowledge of written and spoken English
- Capable of attending regular in-person visits
- Have failed/not a candidate/do not want surgery
- Inadequate response to medication - at least 2 trials
- Meeting ICHD criteria for Classical Trigeminal Neuralgia 13.1.1.1
- Patients with frequency > 10 attacks per week
- Stable dose of medications in the last 2 weeks
Who cannot take part
- Neuromuscular disease
- Secondary or Idiopathic TN, or Painful Trigeminal Neuropathy as defined by the ICHD (13.1.1.2, 13.1.1.3, 13.1.2)
- Pregnant or breast feeding (while it is rare that a patient will be pregnant with TN, there is not sufficient data to say definitively that onabotA is ok to use during pregnancy and nursing, it is still rated Class C)
- On aminoglyocosides
- Not currently enrolled in any other studies
Where in United States
- Meredith BaradStanford, United StatesContact: Meredith Study TeamTaking people
About the trial
What the trial wants to find out
A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.
The 2 groups in the trial
- OnabotulinumtoxinATreatment being tested
Intradermal injections will be placed in the affected trigeminal territories according to a specific facial map that we have developed.
Treatment: OnabotulinumtoxinA 100 UNT [Botox]
- SalinePlacebo, for comparison
The same procedure will be followed as above, but saline will be injected instead of onabotA
Treatment: Sodium Chloride 0.9% for Injection, Preservative Free
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Controlled Trial of Intradermal Injections of OnabotulinumtoxinA vs Saline for Trigeminal Neuralgia.
- Plain-language title
- OnabotulinumtoxinA injections compared with saline for trigeminal neuralgiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 22 January 2026